Last reviewed · How we verify
NCT07163585
Comparison of Oral Brivaracetam Versus Levetiracetam as Monotherapy in Epilepsy
NA trial testing Brivaracetam in Epilepsy in 102 participants. Completed in 31 July 2025.
31 July 2025
Quick facts
| Lead sponsor | RESnTEC, Institute of Research |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 102 |
| Start date | 1 August 2024 |
| Primary completion | 31 July 2025 |
| Estimated completion | 31 July 2025 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Brivaracetam (BRIVARACETAM) — full drug profile →
- Levetiracetam (levetiracetam) — full drug profile →
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
RESnTEC, Institute of Research
Who can join
Adults 1 Month to 14, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Despite increasing clinical use of both agents, there is a paucity of head-to-head comparative data on the safety and efficacy of brivaracetam versus levetiracetam as initial monotherapy in children. The present study was therefore designed to compare the safety and efficacy of oral brivaracetam and levetiracetam as monotherapy in children aged one month to 14 years with newly diagnosed epilepsy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07163585
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Brivaracetam
Trials testing the same drug.
- NCT05899764 — Epileptic Hippocampus in Alzheimer's Disease · Phase 1, PHASE2 · not yet recruiting
- NCT05029960 — Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas · EARLY_PHASE1 · active not recruiting
- NCT04666610 — A Study to Evaluate the Efficacy, Safety, and Tolerability of Brivaracetam as Monotherapy in Patients 2 to 25 Years of A · Phase 3 · active not recruiting
- NCT04715646 — A Study to Test the Safety and Tolerability of Brivaracetam in Children and Adolescents With Seizures · Phase 3 · recruiting
- NCT04379011 — Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury · Phase 1, PHASE2 · completed
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other RESnTEC, Institute of Research trials
Trials by the same sponsor.
- NCT07229885 — Comparison of Early Versus Late Trophic Feeding · NA · completed
- NCT07052136 — Efficacy Comparison Between Levetiracetam and Valproic Acid in Pediatric Patients With Status Epilepticus · NA · completed
- NCT06532409 — Comparison of Efficacy of Oral Amoxicillin Versus Intravenous Ceftriaxone · NA · not yet recruiting
- NCT07053930 — Comparison of the Mean Duration of 3rd Stage of Labour Between Intraumbilical and Intravenous Oxytocin · NA · completed
- NCT07050615 — Comparison of the Frequency of Post-Operative Pain of Continuous Versus Interrupted Suturing Techniques in Episiotomy · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07163585 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RESnTEC, Institute of Research
- Last refreshed: 9 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07163585.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing